FDA Clearance Tracker · P160030
Freestyle Libre Flash Glucose Monitoring System
Last checked: Nov 19, 2026Latest source record: Sep 27, 2017 (this decision)Source: openFDAMethods & limitations
Decided
Sep 27, 2017
Approved
Time to decision
422 days
Received Aug 1, 2016. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P160030
- Device name
- Freestyle Libre Flash Glucose Monitoring System
- Applicant
- Abbott Diabetes Care, Inc.
- Applicant location
- Alameda, CA
- Received
- Aug 1, 2016
- Decided
- Sep 27, 2017
- Decision
- Approved
- Supplements
- 54 in FDA's data for this PMA. See them on the FDA record
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval for the Freestyle Libre Flash Glucose Monitoring System. The FreeStyle Libre Flash Glucose Monitoring System is a continuous glucose monitoring (CGM) device indicated for the management of diabetes in persons age 18 and older. It is designed to replace blood glucose testing for diabetes treatment decisions.The System detects trends and tracks patterns aiding in the detection of episodes of hyperglycemia and hypoglycemia, facilitating both acute and long-term therapy adjustments. Interpretation of the System readings should be based on the glucose trends and several sequential readings over time. The System is intended for single patient use and requires a prescription.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- This is the earliest decision in FDA's data under product code PZE (Sensor, glucose, invasive, non-adjunctive, factory-calibrated, user-initiated).
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Abbott Diabetes Care, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K233537 · Decided Apr 23, 2024 · 172 days after receipt
Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ) · Laboratory Medicine & Pathology
K223435 · Decided Apr 13, 2023 · 150 days after receipt
Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ) · Laboratory Medicine & Pathology
K222447 · Decided Mar 3, 2023 · 200 days after receipt
Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.